宜明昂科(01541.HK)治疗肿瘤药物获内地批准进行临床试验

阿斯达克财经
Yesterday

宜明昂科(01541.HK) 公布,已获国家药监局批准进行IMM01 (替达派西普)联合IMM2510 (珀维拉芙普α),另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10